Oligonucleotide therapy.
Rapid progress in oligonucleotide therapeutics has continued over the past year as major programs established in the past four years have grown and begun to be productive. Important advances were reported in the medicinal chemistry of oligonucleotides and in understanding their pharmacodynamic properties. Significant progress was made in understanding the pharmacokinetic and toxicologic properties of first generation analogs, particularly phosphorothioates and one oligonucleotide, ISIS 2105, entered clinical trials. Additionally, combinatorial approaches designed to identify oligonucleotides that may bind to a variety of targets were reported.
Crooke
S T
ST
Isis Pharmaceuticals, Carlsbad, California 92008.
D000818:Animals; D002460:Cell Line; D015195:Drug Design; D005796:Genes / Q000187:drug effects*; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D009857:Oncogenes / Q000187:drug effects; D063086:Organothiophosphates / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D014780:Viruses / Q000187:drug effects* / Q000235:genetics
D016376:Oligonucleotides, Antisense; D063086:Organothiophosphates